Abstract
Objective: to analyze the incidence of community-acquired pneumonia and acute otitis media in children during the first four years of life in different age groups vaccinated with pneumococcal 13-valent vaccine Prevenar.Materials and methods: medical records of 590 children aged 1 to 5 years were analyzed. All subjects were divided into 2 groups. The first group consisted of vaccinated children (n = 490), born in 2014, and vaccinated against pneumococcal 13-valent vaccine Prevenar. The second group consisted of unvaccinated children (n = 100) born in 2013 and not vaccinated. Each group was divided into subgroups depending on the age period (1—2 years, 2—3 years, 3—4 years, 4—5 years).Results: it is established that the conduct of specific prophylaxis of pneumococcal infection vaccine Prevenar-13 in children during the first 4 years of life effectively reduces the incidence of community-acquired pneumonia (in 7,6 times) and acute otitis media (in 8,5 times). The effectiveness of the vaccine was observed in all age groups. In cases of development of an inoculated child acute otitis reduces the risk of severe forms and complications of the disease. Analysis of the course of the post-vaccination period indicates a high level of safety and good tolerability of the vaccine.Conclusion: Implementation of specific prophylaxis of pneumococcal 13-valent vaccine Prevenar in children during the first four years of life according to the calendar of vaccination effectively reduces the incidence of community-acquired pneumonia (87 %) and acute otitis media (42,8 %) in all age subgroups. In cases of development of an inoculated child acute otitis reduces the risk of severe forms and complications of the disease. Analysis of the course of the post-vaccination period indicates a high level of safety and good tolerability of the vaccine.
Highlights
Анализ заболеваемости внебольничной пневмонией и острым отитом у детей первых четырех лет жизни в разных возрастных группах, привитых пневмококковой
The first group consisted of vaccinated children (n = 490), born in 2014, and vaccinated against pneumococcal 13-valent vaccine Prevenar
Results: it is established that the conduct of specific prophylaxis of pneumococcal infection vaccine Prevenar-13 in children during the first 4 years of life effectively reduces the incidence of community-acquired pneumonia and acute otitis media
Summary
У ДЕТЕЙ ПЕРВЫХ ЧЕТЫРЕХ ЛЕТ ЖИЗНИ В РАЗНЫХ ВОЗРАСТНЫХ ГРУППАХ, ПРИВИТЫХ ПНЕВМОКОККОВОЙ 13-ВАЛЕНТНОЙ ВАКЦИНОЙ ПРЕВЕНАР. Анализ заболеваемости внебольничной пневмонией и острым отитом у детей первых четырех лет жизни в разных возрастных группах, привитых пневмококковой. Цель: провести анализ заболеваемости внебольничной пневмонией и острым отитом у детей первых четырех лет жизни в разных возрастных группах, привитых пневмококковой 13-валентной вакциной Превенар. Результаты: проведение специфической профилактики пневмококковой инфекции вакциной Превенар-13 у детей первых 4 лет жизни эффективно снижает заболеваемость внебольничной пневмонией в 7,6 раза, острым отитом — в 8,5 раз. Заключение: проведение специфической профилактики пневмококковой инфекции 13-валентной вакциной Превенар у детей первых четырех лет жизни, согласно календарю, прививок эффективно снижает заболеваемость внебольничной пневмонией (на 87 %) и острым отитом (на 42,8 %).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
